• RedHill outlined a U.S.-focused specialty pharma strategy built around Talicia, its FDA-cleared H. pylori therapy co-commercialized with Cumberland.
• Net revenue for FY 2025 totaled USD 7.8 million; cash balance USD 4.1 million; market cap about USD 5 million; ADSs about 6,100,000.
• Presentation flagged equity financing capacity of USD 31.7 million via an at-the-market purchase agreement, plus a standby equity purchase agreement.
• Talicia positioned as the leading branded H. pylori prescription among U.S. gastroenterologists, with patent protection cited through 2042.
• Pipeline focus included opaganib across oncology and ARDS, RHB-102 for GI indications, RHB-204 for pulmonary NTM disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief on July 02, 2026, and is solely responsible for the information contained therein.